Subject: PSID Issues Major Update BICX Adds Huge Three State Market VMGI Announces New Line

SCV Client Spotlight
PSID Issues Major Update BICX Adds Huge Three State Market VMGI Announces New Line
Hot Stock to WatchHot Stock to Watch

Company: BioCorRx Inc. (OTCQB: BICX)

End of Day:

Price: 0.1245

Change (%): + 0.0045 (3.75)

Volume: 13,800
BICX Chart

BioCorRx, Inc. Completes License Agreement for Distribution of its Start Fresh Program in Minnesota, Missouri, and Oklahoma

Los Angeles, June 27, 2014 (GLOBE NEWSWIRE) - BioCorRx, Inc. (“the Company”) (OTCQB: BICX), a leader in addiction treatment and rehabilitation programs, announced it has closed the sale for the exclusive license and distribution rights of its Start Fresh Program to multiple wholly owned subsidiaries of Start Fresh Midwest Holdings, LLC, which consist of common majority owners of Fresh Start Private Midwest, LLC. (“Midwest”). Under the terms of the finalized agreement, Midwest will pay BioCorRx, Inc. an upfront license fee plus an ongoing fee per program ordered in the states of Minnesota, Missouri, and Oklahoma.

The combined population of these states is over 15 million people, many of which can benefit from the Start Fresh Program. Minnesota has seen such an increase in opiate addiction that earlier this year the state passed legislation offering immunity from prosecution to those who call for help during an overdose. Along with this new legislation the state also offers training in the administration of overdose reversing drugs to friends, family, and first responders who deal with addicts.

Continue Reading

Top PerformerYesterday's Top Performer

PositiveID Corporation (OTCQB: PSID)

End of Day:

Price: 0.054

Change (%): + 0.001 (1.89)

Volume: 179,927
PSID Chart

PositiveID Publishes Updated Report on Its BioThreat Detection and Diagnostics Solutions and Market Opportunities

DELRAY BEACH, Fla., June 30, 2014 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today published an updated report on its 2014 progress and future market opportunities for its homeland security and medical diagnostics technologies.

“There is a pervasive, global need for advanced biological detection capabilities, where time to detection is critical to stop a biological attack in its tracks,” stated William J. Caragol, PositiveID’s Chairman and CEO. “As evidenced by our current relationships with large commercial and government partners, we believe our M-BAND and Firefly Dx systems offer significant benefits over existing products, including faster, more accurate detection, at a lower cost. The Company is generating revenue for the first time since its formation, and we have issued revenue guidance through the end of 2015 of 4-10 million dollars (2014 and 2015 combined), 3.3 million dollars of which is currently in backlog.”

Continue Reading

SmallCapVoice Clients' News

Verde Media Group, Inc. (Pink Sheets: VMGI)

Verde Media Group Inc. Announces Initial Product Line of Cosmetic Injectables From Beautyject Inc. for North American Launch

LOS ANGELES, June 30, 2014 (GLOBE NEWSWIRE) - Verde Media Group Inc. (OTC:VMGI) has announced the initial product line from its majority-owned subsidiary, Beautyject Inc. Comprised of a slate of needle-free, over-the-counter cosmetic injectables, this new product line is poised for its North American release by a top-tier sales and marketing firm and comfortably occupies its own niche in the industry.

For the first time ever, individuals will be able to administer treatments for superficial lines, minor skin damage, fine wrinkles, moisture and skin elasticity from home or by a beautician, with no risk of needle stick injuries and damage to the skin.

Continue Reading

Other Small Cap News

Company: Cannabis Therapy Corp. (OTCQB: CTCO)

Cannabis Therapy Corp. Views FDA Reclassification Analysis as a Potential Win for Both Industry and Consumers

BOULDER, CO--(Marketwired - Jun 30, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company") a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to note recent media reports that the U.S. Food and Drug Administration ("FDA"), at the request of the Drug Enforcement Administration ("DEA"), is conducting an analysis on whether the U.S. should downgrade the classification of marijuana as a Schedule 1 drug.

Schedule 1 drugs are the most restrictive of the five DEA classifications and are considered substances with no medical benefit and which are highly addictive.

Continue Reading

Market News

By Catherine Boyle: CNBC

The potential pitfalls of the rest of 2014

Halfway into 2014, as trading desks across the world go quiet for the summer, it's time to take stock and take a look at what might lie ahead.

Despite geopolitical shocks from Ukraine and the Middle East, it has been a positive first half overall, with global stocks (as measured by the MSCI world equity index) on track for their fourth straight quarter of gains.

The promised IPO rebound has materialized, with global volume up 44 percent to $104.9 billion via 533 deals, according to Dealogic, but the mergers and acquisitions market hasn't quite bounced back on a similar scale.

Continue Reading

By Lee Brodie:

Cramer: Best bets for second half

With only a handful of days left in June, Jim Cramer is scouring the market, looking for new ideas for the second half.

And as he sifted through a pile of earnings and other data, Chevron grabbed his attention, largely because the stock just broke out of a trading range.

For the past year, Cramer says, Chevron had been stuck in a rut. "It was a stock that needed to be bought every time it dipped below $120 and then sold every time it got to the high $120s," he said.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks